Blood Cancer Talks cover image

Episode 20. Management of Myeloma in LMICs

Blood Cancer Talks

CHAPTER

The Importance of Monitoring Myeloma Markers

After transplant, in myeloma, unfortunately, we cannot give them a treatment-free remission. So basically everybody is on revlimate at least for two to three years. And after that, if there has been two consequent MRD negative, then I discuss with the patient that to hold the limit and watch closely the myeloma markers. Although there is no randomized trial showing that approach is perfectly safe, but there are some single-arm trials now that's coming out.

00:00
Transcript
Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
App store bannerPlay store banner